AUS
NZ
UK
CA
USA
IND
Healt
Anatara Lifesciences (ASX:ANR) Shares Key Findings from GaRP-IBS Phase II Trial with Promising Safety and Secondary Results
April 17, 2025 05:19 PM AEST| By Team Kalkine MediaHighlights,Phase II trial for GaRP-IBS did not meet primary endpoint,Positive results seen in key secondary measures,Product showed strong safety profile with no concerns,Anatara Lifesciences (ASX:ANR) has announced the results of Stage 2 of its Phas...
Clarity Pharmaceuticals Secures Long-Term Copper-64 Supply from Nusano to Bolster Cancer Therapy Pipeline
April 17, 2025 05:14 PM AEST| By Team Kalkine MediaHighlights,Clarity inks multi-year copper-64 supply deal with Nusano,Nusano’s facility supports large-scale isotope production,Agreement strengthens pipeline for oncology diagnostics and therapies,Clarity Pharmaceuticals (ASX:CU6) has announced the s...
Clarity Pharmaceuticals Expands Theranostics Reach Through Isotope Supply Agreement
April 17, 2025 04:30 PM AEST| By Team Kalkine MediaHighlights:,Clarity Pharmaceuticals secures commercial-scale copper-64 supply agreement with Nusano,Nusano’s Utah facility enhances isotope production for cancer-focused theranostic solutions,Agreement strengthens Clarity’s U.S. clinical pipeline and...
Fonterra Gears Up for Potential IPO with Key Leadership Appointment
April 17, 2025 04:28 PM AEST| By Team Kalkine MediaHighlights,Anne Templeman-Jones joins board of Fonterra’s consumer unit,Strategic move fuels IPO and trade sale possibilities,Consumer arm estimated at up to $4 billion,Fonterra Co-operative Group (ASX:FCG), one of the world’s largest dairy exporters...
Clarity Pharmaceuticals Jumps on Breakthrough US Production Deal for Cancer Imaging Isotope
April 17, 2025 04:04 PM AEST| By Team Kalkine MediaHighlights,Clarity inks commercial production deal for copper-64 with Nusano,Shares rise over 12%, topping ASX 200 leaderboard,$11.1M tax incentive to boost product development,Clarity Pharmaceuticals (ASX:CU6) saw a notable surge in its share price...
Lumos Diagnostics Advances FebriDx® Rollout with Medicare Approval Supporting ASX Healthcare Stocks Momentum
April 17, 2025 02:33 PM AEST| By Team Kalkine MediaHighlights:,Lumos Diagnostics secures reimbursement for FebriDx® through key US Medicare contractors.,FebriDx® test added to national reimbursement schedule, expanding access across clinical settings.,Broader Medicare engagement may strengthen outloo...
InhaleRX initiates Phase 1 trial for inhaler designed to treat panic disorder.
April 17, 2025 01:30 PM AEST| By Team Kalkine MediaHighlights,InhaleRX initiates clinical trials for its cannabidiol-based inhaler therapy, IRX-616a.,Study conducted in Adelaide under the supervision of iNGENū CRO Pty Ltd.,Clendon Biotech Capital provides multi-million dollar funding to support clini...
Lumos Diagnostics Wins Key US Medicare Support for FebriDx®, Eyes Wider Market Reach
April 17, 2025 01:00 PM AEST| By Team Kalkine MediaHighlights,Medicare reimbursement secured for,FebriDx,® in major regions,$41.38 per test rate set to begin from April 2025,Broader US market access expected as discussions advance,Lumos Diagnostics Holdings Ltd (ASX:LDX) has taken a major step forwar...
Dissecting the Shareholder Dynamics of Sonic Healthcare Limited (ASX:SHL)
April 17, 2025 12:34 PM AEST| By Team Kalkine MediaHighlights,Individual investors hold significant influence in Sonic Healthcare Limited (SHL).,Institutions account for a substantial 40% ownership.,Insider ownership is notable with a stake worth AU$137 million.,Understanding the distribution of owne...
Is the Recent Stock Performance of Austco Healthcare Limited (ASX:AHC) Linked to Its Robust Fundamentals?
April 17, 2025 12:32 PM AEST| By Team Kalkine MediaHighlights:,Austco Healthcare (ASX:AHC) displays strong financial indicators with a rising return on equity.,Earnings growth remains solid, exceeding broader industry benchmarks over the long term.,Strategic reinvestment of earnings supports operatio...
COH Share Price and JBH Performance: Developments in ASX Healthcare Stocks and Retail Sector
April 16, 2025 05:05 PM AEST| By Team Kalkine MediaHighlights:,COH share price has declined since the start of the year, drawing attention to its recent financial outcomes.,JBH revenue and net profit movements reflect broader trends in consumer electronics retailing.,Focus on,ASX Healthcare Stocks,su...
"Growth" Defines Firebrick's (ASX:FRE) Sales-Focused Quarter
April 16, 2025 03:30 PM AEST| By Team Kalkine MediaHighlights:,Firebrick Pharma expands its Nasodine product line across multiple global markets, including Singapore, the United States, and the South Pacific.,Key collaborations with local partners, such as Innorini Life Sciences and Makans, support t...
PainChek (ASX:PCK) Strengthens Growth Prospects with R&D Boost, FDA Progress, and Infant App Launch
April 16, 2025 03:16 PM AEST| By Team Kalkine MediaHighlights,$1.41M R&D tax refund extends financial runway,US FDA review of Adult App progressing steadily,Infant App launches with strong early reception,PainChek (ASX:PCK),is making notable strides in its mission to transform pain assessment through...
The Share Price of Althea Group Holdings Limited (ASX:AGH) Reflects Market Sentiment Regarding Its Revenues
April 16, 2025 02:33 PM AEST| By Team Kalkine MediaHighlights:,Althea Group Holdings exhibits a low price-to-sales ratio, reflecting its below-industry valuation.,The company has shown positive revenue growth, though it trails behind industry growth projections.,Investor sentiment indicates cautious...
Why Healthcare Tech is on the Radar: A Closer Look at Pro Medicus (ASX:PME)
April 16, 2025 02:10 PM AEST| By Team Kalkine MediaHighlights,PME delivers radiology tech that supports faster diagnostics,Healthcare sector offers stable revenue and long-term growth,PME trades at a premium valuation with rising revenue,Pro Medicus (ASX:PME), a leading healthcare technology provider...
PTX-100 Moves Closer to Market as FDA Grants Fast-Track Status to Prescient Therapeutics
April 16, 2025 01:46 PM AEST| By Team Kalkine MediaHighlights,PTX-100 receives fast-track status from FDA,Promising early results in treating T-cell lymphoma,Phase 2 trials underway across multiple regions,Prescient Therapeutics (ASX:PTX) has achieved a key regulatory milestone, with its lead drug ca...
NeuroScientific (ASX:NSB) Accelerates Stem Cell Advancements with Strategic Acquisition of Isopogen
April 16, 2025 01:32 PM AEST| By Team Kalkine MediaHighlights,NeuroScientific acquires Isopogen and its patented StemSmart technology,Focus on regenerative stem cell therapies for neurodegenerative disorders,New clinical trials planned to drive regulatory path forward,NeuroScientific Biopharmaceutica...
Tryptamine Therapeutics (ASX:TRP) Launches Groundbreaking Psilocybin Trial for Binge Eating Disorder
April 16, 2025 01:14 PM AEST| By Team Kalkine MediaHighlights,New trial with Swinburne University targets binge eating disorder,TRP-8803 infusion aims to assess impact on eating behavior, mental health,Builds on strong Phase 2 results from prior psilocybin studies,Tryptamine Therapeutics (ASX:TRP) ha...
FDA Fast Track Boosts Prescient’s PTX-100 Toward Commercialisation Milestone
April 16, 2025 11:11 AM AEST| By Team Kalkine MediaHighlights,PTX-100 granted Fast Track status by US FDA,Clinical-stage progress enhances commercial pathway,Phase 2 trial in CTCL advancing toward patient enrolment,Prescient Therapeutics (ASX:PTX) has taken a significant step forward in its oncology...
Shareholders Should Not Ignore Pro Medicus Insiders Selling AU$514 Million in Stock
April 15, 2025 10:30 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus Limited (PME) experienced a notable stock price increase of 20% last week.,Insider transactions have favored sales over purchases in the past year, raising interest and curiosity.,Insider ownership stands at 49%, promoting alig...
Advertise your brand on Kalkine Media